ERYTECH to Present at Jefferies Virtual Healthcare Conference
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq &…
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq &…
BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or…
FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Vaxcyte, Inc., formerly known as SutroVax,…
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage…
EMERYVILLE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader…
On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in…
Commercial Launch of Twirla® Expected by Year-End 2020 $71.9 Million in Cash, Cash Equivalents, and…
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the…
BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, Mass., Nov. 12,…
NGM continues to demonstrate the productivity of its research discovery engine and progress against its…
Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022,…
– Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including…
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated…
PORTLAND, Maine, Nov. 12, 2020 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”),…
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH…
MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical…
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases SAN DIEGO, Nov….